, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ) today announced participation at SLEEP 2024, to be held in from . The following will be presented: Presentation Title: "Drug Screening and CRISPR/Cas9 Screening of HCN Channels" Poster Presentation Session: P-17 Poster Number: 10 Presenter: Dr.
, Head of Genetics Presentation Title: "Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency" Poster Presentation Session: P-17 Poster Number: 11 Presenter: Dr. , Head of Genetics Presentation Title: "Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort" Poster Presentation Session: P-22 Poster Number: 146 Presenter: Dr. , Head of Genetics Presentation Title: "Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study" Poster Presentation Session: Late-Breaking Abstracts (LBA); P-31 Poster Number: 451 Presenter: Dr.
, Head of Genetics For more information on SLEEP 2024, please refer to Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma.
Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 / / Collected Strategies SOURCE Vanda Pharmaceuticals Inc..
